| Filed On | Filing |
|---|---|
| 03 Feb 2015 |
8-K: Unregistered Sales of Equity Securities; Material Modification to Rights of Security Holders +1 more
(a) To carry on the business of a healthcare services development company operating in the healthcare field, and to design, manufacture, produce, supply and provide advanced surgical tools and supplies, sutures and wound care products, n... |
| 27 Jan 2015 |
8-K: Departure/Election of Directors or Officers; Compensation
In connection with the completion of the Transactions, and effective as of January 26, 2015, José E. Almeida, Joy A. Amundson, Craig Arnold, Robert H. Brust, Christopher J. Coughlin, Randall J. Hogan, Dennis H. Reilley, Stephen H. Ruscko... |
| 27 Jan 2015 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +6 more
NINTH SUPPLEMENTAL INDENTURE dated as of January 26, 2015, among Covidien International Finance S.A., a Luxembourg company (the “Company”), Covidien Ltd., a Bermuda company (“CLTD”), Covidien plc, a public limited company incorporated un... |
| 22 Jan 2015 |
8-K: Results of Operations and Financial Condition
First-quarter diluted GAAP earnings per share were $1.12; excluding specified items, adjusted diluted earnings per share were $1.11 |
| 12 Jan 2015 |
8-K: Other Events
On January 12, 2015, Covidien plc (the “Company”) announced that the Irish High Court has set January 26, 2015 to hear the Company’s petition to sanction the scheme of arrangement under which Medtronic, Inc. will acquire the Company (the... |
| 06 Jan 2015 |
8-K: Submission of Matters to a Vote of Security Holders; Other Events
THIS ANNOUNCEMENT IS BEING MADE SOLELY TO COMPLY WITH THE REQUIREMENTS OF THE IRISH TAKEOVER RULES. THE INFORMATION SET OUT HEREIN CONCERNING THE RESULTS OF COVIDIEN PLC’S SHAREHOLDER MEETINGS ON JANUARY 6, 2015 WILL ALSO BE SET OUT IN C... |
| 23 Dec 2014 |
8-K: Other Events
As previously disclosed at pages 157 and 158 of the definitive joint proxy statement/prospectus of Covidien plc (“Covidien”) dated November 20, 2014 (the “Definitive Joint Proxy Statement/Prospectus”) under the heading “Legal Proceedings... |
| 04 Dec 2014 |
8-K: Other Events
MINNEAPOLIS AND DUBLIN, Ireland – Dec. 4, 2014 – Medtronic, Inc. (NYSE: MDT) and Covidien plc (NYSE: COV) today announced that the Chinese Ministry of Commerce has cleared Medtronic’s proposed acquisition of Covidien. The proposed acquis... |
| 01 Dec 2014 |
8-K: Other Events
MINNEAPOLIS AND DUBLIN, Ireland – Nov. 28, 2014 – Medtronic, Inc. (NYSE: MDT) and Covidien plc (NYSE: COV) today announced that the European Commission has conditionally cleared Medtronic’s proposed acquisition of Covidien. The clearance... |
| 26 Nov 2014 |
8-K: Other Events
MINNEAPOLIS AND DUBLIN, Ireland – Nov. 26, 2014 – Medtronic, Inc. (NYSE: MDT) and Covidien plc (NYSE: COV) today announced the receipt of U.S. Federal Trade Commission (FTC) clearance of Medtronic’s proposed acquisition of Covidien. |
| 21 Nov 2014 |
8-K: Regulation FD Disclosure
As previously announced, on June 15, 2014, Covidien plc (“Covidien”) and Medtronic, Inc. (“Medtronic”) entered into a transaction agreement, pursuant to which Medtronic Holdings Limited, a new holding company incorporated in Ireland that... |
| 17 Nov 2014 |
8-K: Other Events
MINNEAPOLIS AND DUBLIN – Nov. 17, 2014 – Medtronic, Inc. (NYSE: MDT) and Covidien plc (NYSE: COV) announced that following a hearding today before the Irish High Court the companies have scheduled shareholder meetings for Tuesday, Januar... |
| 12 Nov 2014 |
8-K: Regulation FD Disclosure
On November 7, 2014, in connection with the proposed acquisition of Covidien plc (the “Company”) by Medtronic, Inc., the Company filed a “Notification of Record and Meeting Dates for Stockholder Meetings” with the New York Stock Exchange... |
| 05 Nov 2014 |
8-K: Results of Operations and Financial Condition
Fourth-quarter diluted GAAP earnings per share were $1.13; excluding specified items, adjusted diluted earnings per share were $1.15 |
| 30 Oct 2014 |
8-K: Other Events
Medtronic, Inc. (“Medtronic”) and Covidien plc (“Covidien”) today confirmed that they expect the closing of Medtronic’s acquisition of Covidien to occur in early calendar year 2015. This is based on, among other things, Medtronic’s and C... |
| 24 Oct 2014 |
8-K: Material Impairments
On October 20, 2014, Covidien plc’s management concluded that a non-cash charge was required for the impairment of non-amortizable in-process research and development projects associated with its Vascular Therapies product line. This det... |
| 23 Sep 2014 |
8-K: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation
Section 1.01 Purpose and Intent of the Plan. The purpose of the Plan is to provide Eligible Employees with certain compensation and benefits in the event that such Employee’s employment with the Company or a Subsidiary is terminated invo... |
| 25 Jul 2014 |
8-K: Results of Operations and Financial Condition
Third-quarter diluted GAAP earnings per share were $0.67; excluding specified items, adjusted diluted earnings per share were $1.04, up 14% |
| 22 Jul 2014 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
DUBLIN, Ireland -- July 22, 2014-- Covidien plc (NYSE: COV) today announced that Bryan Hanson, who currently serves as group president, Medical Devices & U.S., will be elevated to the newly created position of group president, Covidien, ... |
| 11 Jul 2014 |
8-K: Results of Operations and Financial Condition; Other Events
We are a global leader in the development, manufacture and sale of healthcare products for use in clinical and home settings. Our products are found in almost every hospital in the United States, and we have a significant and growing pre... |
Loading...